The economic burden of low back pain in KwaZulu-Natal, South Africa: A prevalence-based cost-of-illness analysis from the healthcare provider's perspective.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
01
2022
accepted:
20
09
2022
entrez:
13
10
2022
pubmed:
14
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
Low back pain (LBP) is a multifactorial and the most prevalent musculoskeletal disorder, whose economic burden is of global concern. Evidence suggests that the burden of LBP in increasing and will continue rising with the greatest burden occurring in low-and-middle-income-countries (LMICs). This study sought to determine the economic burden of LBP in KwaZulu-Natal, South Africa from the providers perspective. We used a retrospective prevalence-based cost-of-illness methodology to estimate the direct medical cost of LBP. Direct medical costs constituted costs associated with healthcare utilisation in inpatient care, outpatient care, investigations, consultations, and cost of auxiliary devices. We used diagnostic-specific data obtained from hospital clinical reports. All identifiable direct medical costs were estimated using a top-down approach for costs associated with healthcare and a bottom-up approach for costs associated with inpatient and outpatient care. The prevalence of chronic low back pain CLBP was 24.3% (95% CI: 23.5-25.1). The total annual average direct medical costs associated with LBP was US$5.4 million. Acute low back pain (ALBP) and CLBP contributed 17% (US$0.92 million) and 83% (US$4.48 million) of the total cost, respectively. The per patient total annual average direct medical cost for ALBP and CLBP were US$99.43 and US$1,516.67, respectively. The outpatient care costs contributed the largest share (38.9%, US$2.10 million) of the total annual average direct medical cost, 54.9% (US$1.15 million) of which was attributed to nonsteroidal-anti-inflammatory drugs (NSAIDs). The total average cost of diagnostic investigations was estimated at US$831,595.40, which formed 15.4% of the average total cost. The economic burden of LBP is high in South Africa. Majority of costs were attributed to CLBP. The outpatient care costs contributed the largest share percent of the total cost. Pain medication was the main intervention strategy, contributing more than half of the total outpatient costs. Measures should be taken to ensure guideline adherence. Focus should also be placed towards development of prevention measures to minimise the cost.
Sections du résumé
BACKGROUND
Low back pain (LBP) is a multifactorial and the most prevalent musculoskeletal disorder, whose economic burden is of global concern. Evidence suggests that the burden of LBP in increasing and will continue rising with the greatest burden occurring in low-and-middle-income-countries (LMICs). This study sought to determine the economic burden of LBP in KwaZulu-Natal, South Africa from the providers perspective.
METHODS
We used a retrospective prevalence-based cost-of-illness methodology to estimate the direct medical cost of LBP. Direct medical costs constituted costs associated with healthcare utilisation in inpatient care, outpatient care, investigations, consultations, and cost of auxiliary devices. We used diagnostic-specific data obtained from hospital clinical reports. All identifiable direct medical costs were estimated using a top-down approach for costs associated with healthcare and a bottom-up approach for costs associated with inpatient and outpatient care.
RESULTS
The prevalence of chronic low back pain CLBP was 24.3% (95% CI: 23.5-25.1). The total annual average direct medical costs associated with LBP was US$5.4 million. Acute low back pain (ALBP) and CLBP contributed 17% (US$0.92 million) and 83% (US$4.48 million) of the total cost, respectively. The per patient total annual average direct medical cost for ALBP and CLBP were US$99.43 and US$1,516.67, respectively. The outpatient care costs contributed the largest share (38.9%, US$2.10 million) of the total annual average direct medical cost, 54.9% (US$1.15 million) of which was attributed to nonsteroidal-anti-inflammatory drugs (NSAIDs). The total average cost of diagnostic investigations was estimated at US$831,595.40, which formed 15.4% of the average total cost.
CONCLUSION
The economic burden of LBP is high in South Africa. Majority of costs were attributed to CLBP. The outpatient care costs contributed the largest share percent of the total cost. Pain medication was the main intervention strategy, contributing more than half of the total outpatient costs. Measures should be taken to ensure guideline adherence. Focus should also be placed towards development of prevention measures to minimise the cost.
Identifiants
pubmed: 36227919
doi: 10.1371/journal.pone.0263204
pii: PONE-D-22-00974
pmc: PMC9560048
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Anti-Inflammatory Agents, Non-Steroidal
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0263204Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet. 2016 Oct 8;388(10053):1545-1602
pubmed: 27733282
Ann Rheum Dis. 2014 Jun;73(6):968-74
pubmed: 24665116
Front Pharmacol. 2016 Feb 12;7:21
pubmed: 26903867
Ann Transl Med. 2020 Mar;8(6):299
pubmed: 32355743
Health Econ Rev. 2012 Sep 11;2(1):18
pubmed: 22963680
Spine (Phila Pa 1976). 2005 Aug 1;30(15):1777-85
pubmed: 16094281
Spine (Phila Pa 1976). 2010 Aug 15;35(18):1714-20
pubmed: 21374895
Lancet. 2012 Dec 15;380(9859):2197-223
pubmed: 23245608
Lancet. 2018 Jun 9;391(10137):2356-2367
pubmed: 29573870
Asia Pac J Public Health. 2003;15(2):79-87
pubmed: 15038680
Lancet. 2018 Jun 9;391(10137):2302
pubmed: 29573869
Lancet. 2018 Jun 9;391(10137):2384-2388
pubmed: 29573871
Spine (Phila Pa 1976). 2013 Jan 1;38(1):75-82
pubmed: 23038621
BMC Musculoskelet Disord. 2018 Jun 21;19(1):196
pubmed: 30037323
J Occup Rehabil. 2009 Dec;19(4):419-26
pubmed: 19760488
Spine (Phila Pa 1976). 2012 May 15;37(11):E668-77
pubmed: 22146287
Afr Health Sci. 2014 Sep;14(3):698-706
pubmed: 25352891
J Occup Environ Med. 1998 Dec;40(12):1110-9
pubmed: 9871888
Eur J Health Econ. 2011 Oct;12(5):455-67
pubmed: 20526649
BMJ Glob Health. 2017 Sep 15;2(3):e000284
pubmed: 29225944
Best Pract Res Clin Rheumatol. 2002 Jan;16(1):23-30
pubmed: 11987929
J Adv Nurs. 2005 Mar;49(6):616-23
pubmed: 15737222
BMC Int Health Hum Rights. 2011 Sep 26;11:11
pubmed: 21943099
Spine J. 2008 Jan-Feb;8(1):8-20
pubmed: 18164449
Pain. 1995 Aug;62(2):233-240
pubmed: 8545149
Br J Rheumatol. 1998 Jan;37(1):82-6
pubmed: 9487255